Navigating the Quality and Cap Curves

Navigating the Quality and Cap Curves

A later cycle economy and continued uncertainty means that investors should be remain wary of cyclicals such as small caps, explains Mike Wilson, our CIO and Chief US Equity Strategist.


----- Transcript -----


Welcome to Thoughts on the Market. I'm Mike Wilson, Morgan Stanley’s CIO and Chief US Equity Strategist. Along with my colleagues bringing you a variety of perspectives, today I'll be talking about slowing growth in the context of high valuations.

It's Tuesday, July 30th at 3pm in New York.

So, let’s get after it.

Over the past few weeks, the equity markets have taken on a different complexion with the mega cap stocks lagging and lower quality small caps doing better. What does this mean for investor portfolios? And is the market telling us something about future fundamentals? In our view, we think most of this rotation is due to the de-grossing that is occurring within portfolios that are overweight large cap quality growth and underweight lower quality and smaller cap names.

We have long been in the camp that large cap quality has been the place to be – for equity investors – as opposed to diving down the quality and cap curves. That continues to be the case; though we are watching the fundamental and technical backdrop for small caps closely, and we’re respectful of the pace of the recent move in the space.

For now, however, we continue to think the better risk/reward is to stay up the quality curve and avoid the more cyclical parts in the market like small caps. Our rationale for such positioning is simple — in a later cycle economy where growth is softening or not translating into earnings growth for most companies, large cap quality outperforms.

Exacerbating the many imbalances across the economy is a bloated fiscal budget deficit. In our view, there are diminishing returns to fiscal spending when it starts to crowd out private companies and consumers. As I have been discussing for the past year, this crowding out has contributed to the bifurcation of performance in both the economy and equity markets, while potentially keeping the Fed's Interest rate policy tighter than it would have been otherwise.

While the macro data has been mixed, there is a growing debate around the actual strength of the labor market with the household survey painting a weaker picture than the non-farm payroll data which is based on employer surveys. The bottom line is that we are in a stable, but decelerating late cycle economy from a macro data standpoint. However, on the micro front, the data has not been as stable and is showing a more meaningful deterioration in growth; particularly as it relates to the consumer.

More specifically, earnings revision breadth has broken down recently for many of the cyclical parts of the market. Financials has been a bright spot here but that may be short-lived if the consumer continues to weaken. We continue to favor quality but with a greater focus on defensive sectors like utilities, staples and REITs as opposed to growthier ones like technology. The issue with the growth stocks is valuations and the quality of the earnings for some of the mega cap tech stocks.

The other variable weighing on stocks at the moment is valuations which remain in the top decile of the past 20 years. It’s worth noting that valuations are very sensitive to earnings revisions breadth. The last time revision breadth rolled over into negative territory was last fall. Between July and October 2023, the market multiple declined from 20x to 17x. Two weeks ago, this multiple was 22x and is now 21x. If earnings revisions continue to fade as we expect, it’s likely these valuations have further to fall. With our 12-month base case target multiple at 19x, the risk reward for equities broadly remains quite unfavorable at the moment.

Thanks for listening. If you enjoy the podcast, leave us a review wherever you listen, and share Thoughts on the Market with a friend or colleague today.

Episoder(1510)

Special Episode, Part 2: COVID-19 - How Close Are We to a Vaccine?

Special Episode, Part 2: COVID-19 - How Close Are We to a Vaccine?

In the second of a special two-part episode, we talk with biotech equity analyst Matthew Harrison about market response to new data in the race for a vaccine.

24 Jul 20208min

Special Episode: COVID-19 - Preparing for Fall's Second Wave

Special Episode: COVID-19 - Preparing for Fall's Second Wave

In the first of a special two part episode, we talk with biotech equity analyst Matthew Harrison about new case projections ahead of fall and flu season.

23 Jul 20208min

Michael Zezas: States Look to D.C. to Fill Budget Holes

Michael Zezas: States Look to D.C. to Fill Budget Holes

Local and state governments across the U.S. are eagerly watching whether a new round of stimulus will help them address budget shortfalls. Will Congress deliver?

22 Jul 20202min

Mike Wilson: Adapting to The Ninth Wonder of the World

Mike Wilson: Adapting to The Ninth Wonder of the World

Understanding the regime of financial repression we are under, and recent changes in it, is key for successful investment. Chief Investment Officer, Mike Wilson explains.

20 Jul 20204min

Andrew Sheets: Bracing for Challenges Ahead

Andrew Sheets: Bracing for Challenges Ahead

While July contains a number of potentially positive market events, August and September could present a number of potentially problematic ones.

17 Jul 20203min

Michael Zezas: Coronavirus - Why Another Stimulus Deal is Likely

Michael Zezas: Coronavirus - Why Another Stimulus Deal is Likely

Could a new $1 trillion stimulus deal make its way through the halls of Congress before the summer recess? Why the likelihood of a deal is increasing.

15 Jul 20202min

Mike Wilson: U.S. Markets Weigh Optimism; Uncertainty

Mike Wilson: U.S. Markets Weigh Optimism; Uncertainty

U.S. equities—tech stocks in particular—have powered higher since March lows, but investors are still parsing Q2 earnings, a coming election and rising COVID-19 cases.

13 Jul 20204min

Andrew Sheets: Pressure Testing the “Overoptimistic Markets” Argument

Andrew Sheets: Pressure Testing the “Overoptimistic Markets” Argument

The sharp rebound in stock and corporate bond markets has made some question if markets are a bit too upbeat about a speedy recovery. There’s just one problem with this view.

10 Jul 20203min

Populært innen Business og økonomi

stopp-verden
dine-penger-pengeradet
e24-podden
rss-penger-polser-og-politikk
kommentarer-fra-aftenposten
rss-borsmorgen-okonominyhetene
finansredaksjonen
livet-pa-veien-med-jan-erik-larssen
rss-vass-knepp-show
pengepodden-2
lydartikler-fra-aftenposten
tid-er-penger-en-podcast-med-peter-warren
stormkast-med-valebrokk-stordalen
morgenkaffen-med-finansavisen
rss-sunn-okonomi
okonomiamatorene
rss-rettssikkerhet-bak-fasaden-pa-rettsstaten-norge-en-podcast-av-sonia-loinsworth-og-foreningen-rettssikkerhet-for-alle
lederpodden
utbytte
rss-markedspuls-2